InflaRx NV (IFRX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about InflaRx NV (IFRX)
Go deeper and ask any question about IFRX
Company Performance
Current Price
as of Sep 13, 2024$1.43
P/E Ratio
N/A
Market Cap
$84.2M
Description
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.
Metrics
Overview
- HQJena, TH
- SectorHealth Technology
- IndustryBiotechnology
- TickerIFRX
- Price$1.43-0.69%
Trading Information
- Market Cap$84.20M
- Float82.92%
- Average Daily Volume (1m)74,376
- Average Daily Volume (3m)69,607
- EPS-$0.86
Company
- Revenue$0.11M
- Rev Growth (1yr)N/A
- Net Income-$14.91M
- Gross Margin-5,376.69%
- EBITDA Margin-240,277.07%
- EBITDA-$16.44M
- EV$23.16M
- EV/Revenue202.13
- P/EN/A
- P/S735.02